Browsing Tag
Tempus
4 posts
AVCT stock near 52-week high as Avacta Group pre|CISION data challenges Enhertu benchmark at AACR 2026
Avacta Group (AIM: AVCT) AACR 2026 data show AVA6103 outperforms Enhertu on tumor selectivity while AVA6207 delivers first in vivo dual payload results. Read our analysis.
How AI is transforming cancer diagnosis and treatment planning in 2025
AI is reshaping cancer care—improving diagnosis, guiding treatment, and boosting efficiency across hospitals. Discover how it's redefining oncology workflows in 2025.
Tempus and AstraZeneca expand collaboration to enhance cancer care with AI
Tempus, a pioneer in artificial intelligence and precision medicine, has announced an expansion of its collaboration with pharmaceutical…
Tempus revolutionizes precision medicine with AI-enabled Tempus One integration into Lens platform
Tempus, a pioneering company in the field of artificial intelligence and precision medicine, has announced the integration of…